CC
MDGL icon

Caxton Corporation’s Madrigal Pharmaceuticals MDGL Stock Holding History

Caxton Corporation’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,999
Closed -$233K – 29
2018
Q1 		$233K Sell
1,999
-419
-17% -$51.7K 0.25% 18
2017
Q4 		$222K Buy
+2,418
New +$138K 0.27% 18
2016
Q4 		– Sell
-506,738
Closed -$6.42M – 16
2016
Q3 		$6.42M Sell
506,738
-115,281
-19% -$1.12M 28.77% 2
2016
Q2 		$5.67M Buy
622,019
+1,881
+0.3% +$22.6K 6.39% 3
2016
Q1 		$5.21M Buy
620,138
+227
+0% +$1.9K 7.19% 4
2015
Q4 		$7.64M Sell
619,911
-439,207
-41% -$12.1M 32.03% 1
2015
Q3 		$64.5M Buy
1,059,118
+227
+0% +$16.4K 87% 1
2015
Q2 		$82.6M Buy
1,058,891
+87
+0% +$7.3K 87.47% 1
2015
Q1 		$71.9M Buy
1,058,804
+196,006
+23% +$16.8M 85.78% 1
2014
Q4 		$80M Buy
862,798
+87
+0% +$9K 92.06% 1
2014
Q3 		$90.9M Buy
862,711
+8,658
+1% +$1.2M 93.55% 1
2014
Q2 		$122M Buy
854,053
+35,786
+4% +$5.23M 94.25% 1
2014
Q1 		$123M Sell
818,267
-72
-0% -$14.2K 94.21% 1
2013
Q4 		$150M Buy
818,339
+143,072
+21% +$26.2M 95.29% 1
2013
Q3 		$149M Buy
675,267
+71
+0% +$15.1K 99.87% 1
2013
Q2 		$118M Buy
+675,196
New +$176M 99.78% 1

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Caxton Corporation's MDGL Position: Q2 2018 in Review

Caxton Corporation sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2018, closing a stake of 1,999 shares — an estimated $233K sold.

Caxton Corporation first reported a position in MDGL in Q2 2013 and held it in 16 quarters. The position peaked at $150M in Q4 2013. 148 funds tracked by Wall St. Rank hold MDGL as of Q2 2018.

  • Caxton Corporation reported no remaining Madrigal Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Caxton Corporation sold 1,999 Madrigal Pharmaceuticals shares in Q2 2018, an estimated $233K.
  • Caxton Corporation first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Caxton Corporation's Madrigal Pharmaceuticals position peaked at $150M in Q4 2013.
  • 148 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2018.

Based on Caxton Corporation's 13F filing for Q2 2018, filed 14 Aug 2018.